SUCCINYLCHOLINE CHLORIDE INJECTION USP SOLUTION

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

SUCCINYLCHOLINE CHLORIDE

Verfügbar ab:

HIKMA CANADA LIMITED

ATC-Code:

M03AB01

INN (Internationale Bezeichnung):

SUXAMETHONIUM

Dosierung:

20MG

Darreichungsform:

SOLUTION

Zusammensetzung:

SUCCINYLCHOLINE CHLORIDE 20MG

Verabreichungsweg:

INTRAVENOUS

Einheiten im Paket:

15G/50G

Verschreibungstyp:

Prescription

Therapiebereich:

NEUROMUSCULAR BLOCKING AGENTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0105141001; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

2021-05-05

Fachinformation

PRESCRIBING INFORMATION
Pr
Succinylcholine Chloride Injection USP
20 mg/mL
Sterile Solution
Intravenous
NEUROMUSCULAR BLOCKING AGENT
Hikma Canada Limited
5995 Avebury Road, Suite 804
Mississauga, Ontario
L5R 3P9
Date of Preparation:
April 22, 2022
Control no. 262697
_Succinylcholine Chloride Injection USP_
Page 2 of 14
PRESCRIBING INFORMATION
NAME OF DRUG
Pr
Succinylcholine Chloride Injection USP
THERAPEUTIC CLASSIFICATION
Neuromuscular Blocking Agent
ACTION AND CLINICAL PHARMACOLOGY
Succinylcholine is an ultra short-acting, depolarizing-type, skeletal
muscle relaxant. As does
acetylcholine, it combines with the cholinergic receptors of the motor
end plate to produce
depolarization. This depolarization may be observed as fasciculations.
Subsequent
neuromuscular transmission is inhibited so long as adequate
concentration of succinylcholine
remains at the receptor site. Onset of flaccid paralysis is rapid
(less than one minute after i.v.
administration), and with single administration lasts approximately 4
to 6 minutes.
Succinylcholine is rapidly hydrolysed by plasma cholinesterase to
succinylmonocholine (which
possesses clinically insignificant depolarizing muscle relaxant
properties) and then more slowly
to succinic acid and choline (see PRECAUTIONS). About 10% of the drug
is excreted
unchanged in the urine. The paralysis following administration of
succinylcholine chloride is
progressive, initially involving consecutively the levator muscles of
the face, muscles of the
glottis and finally the intercostals and the diaphragm and all other
skeletal muscles.
Succinylcholine has no direct action on the uterus or other smooth
muscle structures. Because
it is highly ionized and has low fat solubility, it does not readily
cross the placenta.
Tachyphylaxis occurs with repeated administration (see PRECAUTIONS).
Depending on the dose and duration of succinylcholine administration,
the characteristic
depolarizing neuromuscular block (Phase I block) may change to a block
with characteristics
superficially resembling a nondep